TESTOSTERONE PROPIONATE
Clinical safety rating: avoid
Corticosteroids may increase edema risk and anticoagulants may have increased effects Can cause polycythemia and increased risk of cardiovascular events.
Testosterone propionate is a short-acting androgen receptor agonist. It binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
| Metabolism | Testosterone propionate is hydrolyzed to testosterone by esterases. Testosterone is metabolized primarily in the liver via CYP3A4 and 5α-reductase to dihydrotestosterone (DHT) and other metabolites, which undergo further conjugation and renal excretion. |
| Excretion | Renal: 90% (as glucuronide and sulfate conjugates); Fecal/Biliary: 10%. |
| Half-life | Terminal half-life: 0.8–1.2 hours (rapid elimination due to short ester chain; requires frequent dosing). |
| Protein binding | 97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | 0.6–0.8 L/kg (distributes widely into tissues; low Vd reflects high protein binding). |
| Bioavailability | Intramuscular: 100% (by injection); Oral: <5% (extensive first-pass metabolism; not used orally). |
| Onset of Action | Intramuscular: 24-48 hours; Subcutaneous: 24-48 hours; Transdermal: not applicable for propionate. |
| Duration of Action | Intramuscular: 2-3 days (short-acting; requires injection every 2-3 days for sustained effects). |
50-400 mg intramuscularly every 2-4 weeks. For androgen replacement, 50-100 mg IM every 2 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment; GFR 10-50 mL/min: consider dose reduction by 25-50% due to accumulation; GFR < 10 mL/min: avoid use or use with extreme caution, monitoring for fluid retention and hypertension. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor liver function; Child-Pugh C: contraindicated due to risk of hepatotoxicity and fluid retention. |
| Pediatric use | Not recommended for pediatric use in growth or development. For delayed puberty, 25-50 mg IM every 2-4 weeks for 4-6 months; individualize based on response. Weight-based dosing: 2-5 mg/kg IM every 2-4 weeks (use with caution). |
| Geriatric use | Initiate at low end of dosing range (e.g., 25-50 mg IM every 2-4 weeks) due to increased risk of prostatic hyperplasia, cardiovascular events, and fluid retention. Monitor serum testosterone levels, hematocrit, and prostate-specific antigen (PSA) periodically. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Corticosteroids may increase edema risk and anticoagulants may have increased effects Can cause polycythemia and increased risk of cardiovascular events.
| FDA category | Contraindicated |
| Breastfeeding | Contraindicated during breastfeeding. Testosterone propionate is excreted into breast milk; M/P ratio not determined. Potential for adverse effects in the infant (androgen exposure). |
| Teratogenic Risk | Contraindicated in pregnancy. Testosterone propionate is an androgen; exposure during the first trimester can cause virilization of the female fetus (clitoromegaly, labial fusion). During second and third trimesters, continued virilization risk. Not recommended at any stage. |
■ FDA Black Box Warning
WARNING: VIRILIZATION IN WOMEN AND PRECOCIOUS PUBERTY IN CHILDREN. Prolonged use in women may cause hirsutism, voice deepening, and clitoral enlargement; in children, it may cause premature epiphyseal closure and precocious sexual development. Testosterone propionate should not be used in women of childbearing potential unless the benefit clearly outweighs the risk of virilization.
| Common Effects | Acne |
| Serious Effects |
["Men with breast cancer or known or suspected prostate cancer","Pregnancy (may cause fetal harm) and women who may become pregnant","Hypersensitivity to testosterone propionate or any component of the formulation","Severe hepatic impairment or known hepatotoxicity related to androgens","Male with primary hypogonadism with contraindications to testosterone therapy (e.g., untreated obstructive sleep apnea, uncontrolled heart failure)"]
| Precautions | ["Risk of erythrocytosis and increased hematocrit; monitor hemoglobin/hematocrit periodically.","May worsen sleep apnea, especially in patients with obesity or chronic lung disease.","May cause fluid retention and exacerbate heart failure, hypertension, or renal disease.","Can accelerate growth of androgen-sensitive prostate cancer and benign prostatic hyperplasia; monitor prostate-specific antigen (PSA).","May cause gynecomastia, oligospermia, and reduced fertility in males.","Risk of hepatotoxicity with oral methyltestosterone, but less concern with injectable testosterone propionate; still monitor liver function.","May affect bone growth in children; use with caution in pediatric patients.","May cause psychiatric effects such as libido changes, depression, or aggression."] |
Loading safety data…
| Fetal Monitoring | If accidental exposure during pregnancy, monitor fetal development with ultrasound for ambiguous genitalia. Maternal monitoring: signs of virilization, hirsutism, acne, voice changes, liver function tests, lipid profile, and blood pressure. |
| Fertility Effects | Testosterone propionate suppresses gonadotropin secretion, leading to oligospermia or azoospermia in males, and anovulation, menstrual irregularities, and reduced fertility in females. Effects may be reversible upon discontinuation. |